MedPath

ADHERA THERAPEUTICS, INC.

ADHERA THERAPEUTICS, INC. logo
🇺🇸United States
Ownership
Public
Established
1983-01-01
Employees
1
Market Cap
-
Website
http://www.adherathera.com

Clinical Trials

0

Active:0
Completed:0

Trial Phases

0 Phases

Drug Approvals

1

FDA:1

Drug Approvals

Prestalia

Approval Date
Oct 25, 2019
FDA

Clinical Trials

No trials found

News

Phase II Trial of Niraparib-Dostarlimab Combination Fails to Meet Primary Endpoint in Recurrent Head and Neck Cancer

A phase II trial evaluating niraparib and dostarlimab combination therapy in recurrent/metastatic head and neck squamous cell carcinoma was terminated early for futility after achieving only 20% clinical benefit versus the target of 50%.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.